Lonza Group AG - Earnings Release 2024

News Details

Ad-hoc | 25 July 2024 06:55

Lonza Group H1 2024 Performance Well On Track to Deliver Full-Year Outlook: Sales Up 1.8% CER and 29.2% CORE EBITDA Margin

Lonza Group AG / Key word(s): Half Year Results

25-Jul-2024 / 06:55 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.

Ad hoc announcement pursuant to Art. 53 LR

Lonza delivered sales of CHF 3.1 billion, growing 1.8% 1 CER
CHF 893 million CORE EBITDA resulted in a margin of 29.2%
Robust performance in CDMO business, with headwinds in the capsules business within the Capsules & Health Ingredients (CHI) division
Solid free cash flow at CHF 296 million
Group Outlook 2024 confirmed: flat CER sales growth and CORE EBITDA margin in high twenties
Mid-Term Guidance 2024 – 2028, upgraded in March, confirmed

Group Financial Summary


CHF million	HYR 2024	YoY change (in %)	HYR 2023
Sales in AER	3,057	(0.7)	3,078
EBITDA	862	(4.1)	899
Margin in %	28.2		29.2
CORE EBITDA	893	(3.1)	922
Margin in %	29.2		30.0

For more details on performance and financials, please refer to the Half-Year 2024 Presentation , Half-Year 2024 Report and Alternative Performance Measures (APM) 2024 Repor t .

1 Sales growth figures, expressed as a percentage (%), are at Constant Exchange Rate (CER)

2 Actual Exchange Rate

About Lonza

Lonza is one of the world’s largest healthcare manufacturing organizations. Working across five continents, our global community of around 18,000 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market. United by our vision to bring any therapy to life, we support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments.

Our business is structured to meet our customers’ complex needs across four divisions: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. Our company generated sales of CHF 3.1 billion with a CORE EBITDA of CHF 893 million in Half-Year 2024 . Find out more at www.lonza.com

Follow @Lonza on LinkedIn

Follow @LonzaGroup on X

Lonza Contact Details

Victoria Morgan

Head of External Communications

Lonza Group Ltd

Tel +41 61 316 2283

[email protected]

Daniel Buchta

Investor Relations

Lonza Group Ltd

Tel +41 61 316 2985

[email protected]

End of Inside Information


Language:	English
Company:	Lonza Group AG
	Münchensteinerstrasse 38
	4052 Basel
	Switzerland
Phone:	+4161 316 81 11
Internet:	www.lonza.com
ISIN:	CH0013841017
Valor:	1384101
Listed:	SIX Swiss Exchange
EQS News ID:	1953479